Skip to Content

Novo Nordisk A/S ADR NVO

Morningstar Rating
$133.18 +1.64 (1.25%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Novo Nordisk's Cardiometabolic Innovation Supports a Wide Moat

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $50 billion-plus diabetes treatment market and roughly half of the more than $15 billion insulin market. Diabetes' prevalence is expected to soar in coming decades as a result of an increasingly overweight and aging population, and we expect Novo to maintain its wide moat as it continues to dominate in diabetes and obesity therapy innovation.

Price vs Fair Value

NVO is trading at a 679% premium.
Price
$131.54
Fair Value
$67.00
Uncertainty
High
1-Star Price
$225.20
5-Star Price
$91.30
Economic Moat
Jslxk
Capital Allocation
Lnzpstggwt

Bulls Say, Bears Say

Bulls

Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.

Bears

Tresiba's strong profile in the long-acting insulin market hasn't been enough to defend it from U.S. pricing pressure due to competition from Sanofi and Lilly, and biosimilar insulins have weighed on category pricing since 2017.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NVO is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$131.54
Day Range
$131.85133.26
52-Week Range
$77.96148.15
Bid/Ask
$133.18 / $133.38
Market Cap
$593.08 Bil
Volume/Avg
2.7 Mil / 4.0 Mil

Key Statistics

Price/Earnings (Normalized)
45.42
Price/Sales
16.60
Dividend Yield (Trailing)
1.04%
Dividend Yield (Forward)
1.04%
Total Yield
1.72%

Company Profile

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
66,015

Competitors

Valuation

Metric
NVO
LLY
SNY
Price/Earnings (Normalized)
45.4291.7010.66
Price/Book Value
41.0260.261.66
Price/Sales
16.6021.562.51
Price/Cash Flow
38.8789.6012.38
Price/Earnings
NVO
LLY
SNY

Financial Strength

Metric
NVO
LLY
SNY
Quick Ratio
0.490.680.83
Current Ratio
0.701.351.27
Interest Coverage
45.8214.1111.03
Quick Ratio
NVO
LLY
SNY

Profitability

Metric
NVO
LLY
SNY
Return on Assets (Normalized)
30.91%11.20%8.05%
Return on Equity (Normalized)
95.22%57.69%14.38%
Return on Invested Capital (Normalized)
73.76%20.65%10.85%
Return on Assets
NVO
LLY
SNY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
XbssrxcyXsxbfm$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
YlrzyxhwYbqrzr$117.2 Bil
Moderna Inc
MRNA
HkprfjzmGqnm$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
WnysxlzvHcldkj$30.1 Bil
argenx SE ADR
ARGX
WnvjppgytLxnz$28.0 Bil
BioNTech SE ADR
BNTX
SkqpcqbDzrp$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
XtvspfbfQhsymb$16.0 Bil
United Therapeutics Corp
UTHR
RfwmnxvsBrqh$14.6 Bil
Incyte Corp
INCY
LrjmsvqwqJcwnsr$13.0 Bil

Sponsor Center